诱导EGFR-TKI的DPP4驱动肺癌中持久性细胞的代谢重编程
Yuanzhou Zhang1, Xiaojun Zhang1, Xupeng Yang2
1State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
概括
用西塔利普丁向迪佩基酶4 (DPP4) 可以克服EGFR突变肺癌中药物耐受性. 这种组合疗法减少了残留疾病和复发,改善了小鼠的生存率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 表皮生长因子受体 (EGFR) 突变驱动肺癌,细胞进入耐药性持久 (DTP) 状态,然后抵抗EGFR-tyrosine kinase抑制剂 (TKI).
- 了解DTP细胞的代谢适应对于开发有效的治疗策略至关重要.
研究的目的:
- 在DTP肺癌细胞中识别治疗点.
- 调查二乙酶4 (DPP4) 在DTP细胞代谢和存活中的作用.
- 为了评估结合TKI与DPP4抑制剂的疗效.
主要方法:
- 建立和描述两个DTP肺癌细胞系.
- 代谢途径的分析,包括氧化酸化和脂肪酸代谢.
- 对DPP4-MEK-Nrf2信号通路的研究.
- 在体内研究将奥西默蒂尼布 (EGFR-TKI) 与西塔格利丁 (DPP4抑制剂) 结合起来.
主要成果:
- DPP4被确定为DTP细胞的关键标,这些细胞依赖于氧化酸化和增强脂肪酸代谢.
- DPP4通过CPT1A促进脂肪酸的吸收和氧化,并通过DPP4-MEK-Nrf2通路维持线粒体功能.
- 与奥西默蒂尼布和西塔格利普丁的联合治疗抑制了瘤进展,减少了残留疾病,并降低了小鼠的复发率.
结论:
- 在EGFR-TKI耐受性肺癌细胞中,DPP4是代谢适应和生存的关键媒介.
- 针对DPP4与EGFR-TKI结合,提供了一种有希望的策略,以消除持久细胞并防止复发.
- 这种方法有可能改善肺癌患者的长期结果.
关键词:
DPP4 DPP4 DPP4 DPP4 DPP4 DPP4 DPP4 DPP4 DPP4 DPP4 DPP4DTP DTP DTP DTP DTP DTP DTP DTP DTP DTP DTP DTP DTP DTP DTP DTP在 EGFR-Tki 中.奥克斯福斯 (OXPHOS) 是一个肺癌是一种肺癌.更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
13.3K
相关概念视频
02:38Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:53Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K